Although a prior observation suggested that TMB increases upon recurrence post-platinum therapy in BRCA1/2 mutation-associated ovarian cancers, the study included only five primary/recurrent ovarian tumor pairs17. This evidence concerns the gene BRCA1 and ovarian neoplasm.